Document:

Alliance Expansion Agreement, dated May 4, 2007

 EXHIBIT 10.1 
 [EXPLANATORY NOTE: “*” INDICATES THE PORTION OF THIS EXHIBIT THAT HAS BEEN 
 OMITTED AND
SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION 
 PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT.] 
 ALLIANCE EXPANSION AGREEMENT 
 This agreement (the “Alliance Expansion Agreement”) is made this 4th day of May, 2007 to the Development Alliance and Supply Agreement of May 7, 2002 as amended pursuant to the Amendment to Development and Supply Agreement
of 3 November, 2003), (the “Alliance”) between Biosense Webster, Inc. (“Biosense Webster”) and Stereotaxis, Inc. (“Stereotaxis”). 
 RECITALS 
 WHEREAS, pursuant to the Alliance the parties have successfully co-developed and
commercialized 4mm thermocouple RF mapping and ablation catheters that they believe are providing compelling therapeutic solutions for certain major disease states in electrophysiology. These 4mm catheters include devices incorporating
Biosense’s proprietary catheter technology and Stereotaxis unique proprietary magnetic navigation technology, and also devices that additionally incorporate Biosense’s unique proprietary 3D catheter location sensing
(“localizing”) technology; and 
 WHEREAS, pursuant to the Alliance the parties are co-developing and commercializing a range of
additional mapping and ablation catheters; and 
 WHEREAS, the parties desire to extend for a period approximating two years their Alliance
specifically regarding development and commercialization of catheters they believe have significant potential to become a new standard of care for complex ablations, which comprise magnetically navigable catheters incorporating Biosense’s
unique proprietary open irrigation intellectual property and technology. These include a magnetically navigable open irrigation catheter (a Partnered NL Catheter), and a magnetically navigable open irrigation catheter that additionally incorporates
Biosense’s localizing technology (a Daughter Product) (together, the “Magnetic Irrigation Catheters”); and 
 WHEREAS the
parties also desire to evaluate additional potential collaborations regarding their technologies. 
 NOW, THEREFORE the parties agree as
follows: 
  

	 	1.	Interpretation. Terms and definitions used in the Alliance will have the same meaning in this Alliance Expansion Agreement unless otherwise indicated. References to this Alliance
Expansion Agreement or provisions hereof also include references to the terms of the Alliance, which are incorporated herein by reference. Unless expressly amended herein, the Alliance remains in full force and effect. In the event of conflict
between this Alliance Expansion Agreement and the Alliance, Development Alliance and Supply Agreement of May 7, 2002 as amended pursuant to the Amendment to Development and Supply Agreement of 3 November, 2003, this Alliance Expansion
Agreement will control. 

  

	 	2.	For the avoidance of doubt only, and without limitation, references in the Alliance to Partnered NL Catheters and Daughter Products will include Magnetic Irrigation Catheters of
each. 

  

	 	3.	Except as set forth in Section 5(i) below, the Term and the Amendment Exclusivity Period related to Daughter Products and Partnered NL Catheters will expire on
December 31, 2009. For the avoidance of doubt, such expiration dates will apply only with respect to such disposable devices and not with respect to Compatible CARTO Systems, Compatible NIOBE Systems or other relevant systems that are subject
to the terms of the Alliance. 

  

	 	4.	The aggregate Revenue Share for all Daughter Products and Partnered NL Catheters, including without limitation the Magnetic Irrigation Catheters, will be increased by *
beginning April 1, 2007 and thereafter during any period in which any such catheters are distributed pursuant to the Alliance (as amended by this Alliance Expansion Agreement). 

	 	5.	Provisions related solely to Magnetic Irrigation Catheters: 

  

	 	(i)	The Term and the Amendment Exclusivity Period related to Magnetic Irrigation Catheters and open irrigation catheter technology only will expire on December 31, 2011.

  

	 	(ii)	Without limitation, the period for continuity of distribution of the Magnetic Irrigation Catheters only, following termination or expiration of the Alliance, as set forth in
Section 11.2 of the Amendment to Development and Supply Agreement of 3 November, 2003, will become operative on December 31, 2011. 

  

	 	(iii)	Without limitation, both parties will carry out their obligations regarding development and commercialization of the Magnetic Irrigation Catheters in a commercially reasonable
manner, and based on such resource allocations as are reasonably necessary to achieve the same; and 

  

	 	(iv)	Additional to the provisions set forth in Section 3 above, the Revenue Share in respect of the Magnetic Irrigation Catheters that will be applicable during * will be
increased by *. 

  

	 	6.	The maximum aggregate Revenue Share calculated in accordance with Section 7 of the Development Alliance and Supply Agreement of May 7, 2002 (computed as if all
contingencies and conditions favorable to Stereotaxis set forth in such Section were met) and in accordance with Section 4 of the Amendment to Development and Supply Agreement of 3 November, 2003 (computed as if all contingencies and
conditions favorable to Stereotaxis set forth in such Section were met) is not affected by the provisions of Sections 4 and 5(iv) above. 

  

	 	7.	Without limitation to Section 5 above, and for the avoidance of doubt, any calculations of Stereotaxis’ Revenue Share will be made on the basis that the incremental
Revenue Share set forth in Section 7 of the Development Alliance and Supply Agreement of May 7, 2002 will apply following the sixth anniversary of the execution of such agreement and thereafter during any period in which any Daughter
Product or Partnered NL Catheter is distributed pursuant to the Alliance (as amended by this Alliance Expansion Agreement). 

  

	 	8.	The parties will evaluate in a commercially reasonable manner the potential for additional collaborations (which may be exclusive or non-exclusive) in the fields of:

  

	 	(i)	Angiogenesis for cardiology. The parties intend to consider existing demand in the angiogenesis research and development market for precise, predictable and repeatable delivery of
biologics (including without limitation stem cells, growth factors and gene therapy biologics) to targeted cardiovascular tissue for applications that may include (a) regeneration at areas of necrotic heart tissue in chronic heart failure
patients and (b) enhancing perfusion in patients with moderate to severe ischemic heart disease. The parties also wish to assess the potential significance of their combined technologies in light of the regulatory requirement from FDA that an
application for the delivery of biologics for such angiogenesis will only be considered in conjunction with or following the clearance and/or approval of the delivery device to be used; and 

  

	 	(ii)	Vascular navigation and associated applications for cardiology. 

  

	 	9.	IN WITNESS WHEREOF, the Parties hereto have caused this Alliance Expansion Agreement to be signed by duly authorized officers or representatives. 

  

	
	/S/ URI YARON
	 Biosense Webster, Inc. by
 Uri Yaron,
Senior Director, Worldwide New Business Development

	
	/S/ BEVIL HOGG
	 Stereotaxis, Inc. by
 Bevil Hogg, Chief
Executive OfficerStereotaxis, Inc. 2002 Stock Incentive Plan, as amended May 24, 2007.

 Exhibit 10.2 
 STEREOTAXIS, INC. 
 2002 STOCK INCENTIVE PLAN 
 As Amended and Restated effective May 24, 2007 
 1. Objectives. 
 The Stereotaxis, Inc. 2002 Stock Incentive Plan (the “Plan”) is designed to attract, motivate and
retain selected employees of, and other individuals providing services to, the Company. These objectives are accomplished by making long-term incentive and other awards under the Plan, thereby providing Participants with a proprietary interest in
the growth and performance of the Company. 
 2. Definitions. 
 (a) “Awards”—The grant of any form of stock option, performance share award, or restricted stock award, whether granted singly, in combination or in tandem, to a Participant pursuant to such
terms, conditions, performance requirements, limitations and restrictions as the Committee may establish in order to fulfill the objectives of the Plan. 
 (b) “Award Agreement”—An agreement between the Company and a Participant that sets forth the terms, conditions, performance requirements, limitations and restrictions applicable to an Award.

 (c) “Board”—The Board of Directors of the Company. 
 (d) “Code”—The Internal Revenue Code of 1986, as amended from time to time. 
 (e) “Committee”—The committee designated by the Board to administer the Plan and chosen from those of its members, or, in the
absence of any such Committee, the Board. 
 (f) “Company”—Stereotaxis, Inc., a Delaware corporation. 
 (g) “Fair Market Value”—The last sale price, regular way, or, in case no such sale takes place on such date, the average of the
closing bid and asked prices, regular way, of the Shares, in either case as reported in the principal consolidated transaction reporting system with respect to securities listed or admitted to trading on the New York Stock Exchange, Inc. (the
“NYSE”) or, if the Shares are not listed or admitted to trading on the NYSE, as reported in the principal consolidated transaction reporting system with respect to securities listed on the principal national securities exchange on which
the Shares are listed or admitted to trading or, if the Shares are not listed or admitted to trading on any national securities exchange, the last quoted sale price on such date or, if not so quoted, the average of the high bid and low asked prices
in the over-the-counter market on such date, as reported by the National Association of Securities Dealers, Inc. Automated Quotations System or such other system then in use, or, if on any such date the Shares are 

 
not quoted by any such organization, the average of the closing bid and asked prices on such date as furnished by a professional market maker making a market
in the Shares selected by the Committee. If the Shares are not publicly held or so listed or publicly traded, the determination of the Fair Market Value per Share shall be made in good faith by the Committee. 
 (h) “Fiscal Year”—The fiscal year of the Company, as the same may be changed from time to time. 
 (i) “Incentive Stock Option”—A stock option intended to meet the requirements of Section 422 of the Code and the regulations
thereunder. 
 (j) “Nonqualified Stock Option”—A stock option which is not an Incentive Stock Option. 
 (k) “Participant”—An individual to whom an Award has been made under the Plan. Awards may be made to employees of the Company, or
any of its subsidiaries (including subsidiaries of subsidiaries), or any other entity in which the Company has a significant equity or other interest, as determined by the Committee, as well as individuals providing services to the Company;
provided, that Incentive Stock Options may only be granted to employees of the Company or any of its subsidiaries (including subsidiaries of subsidiaries). 
 (l) “Performance Period”—A period of one or more consecutive Fiscal Years over which one or more of the performance criteria listed in Section 5(e) shall be measured pursuant to the grant of
Awards (whether such Awards take the form of stock options, performance share awards, long term cash incentives or stock ownership incentive awards). Performance Periods may overlap one another. 
 (m) “Shares” or “Stock”—Authorized and issued or unissued shares of common stock of the Company. 
 3. Stock Available for Awards. 
 Subject to adjustment pursuant to Section 12, the number of shares that may be issued under
the Plan for Awards granted wholly or partly in stock during the term of the Plan is 7,110,998.1 Shares of Stock may be made available from the authorized
but unissued shares of the Company, from shares held in the Company’s treasury and not reserved for some other purpose, or from shares purchased on the open market. For purposes of determining the number of shares of Stock issued under the
Plan, no shares shall be deemed issued until they are actually delivered to a Participant, or such other person in accordance with Section 9. Shares covered by Awards that either wholly or in part are 
  

	 1
	 The shares available include (i) the 1,000,000 share increase as approved by
the stockholders on May 24, 2007, (ii) the shares originally included in the Plan and that were available under the Stereotaxis, Inc. 1994 Stock Option Plan, and (iii) the shares that were added annually on January 1, 2003, 2004,
2005, 2006 and 2007, respectively, pursuant to the terms of the Plan. Each of the foregoing share amounts reflect the 1-for-3.6 reverse stock split completed in July 2004. 

  

 2 

 
not earned, or that expire or are forfeited, terminated, canceled, settled in cash, payable solely in cash or exchanged for other Awards, shall be available
for future issuance under Awards. Further, shares tendered to the Company in connection with the exercise of stock options, or withheld by the Company for the payment of tax withholding on any Award, shall also be available for future issuance under
Awards; provided, however, that not more than 5,194,851 shares may be used for the grant of Incentive Stock Options. 
 4. Administration. 

The Plan shall be administered by the Committee, which shall have full power to select Participants, to interpret the Plan, and to adopt such rules,
regulations and guidelines for carrying out the Plan as it may deem necessary or proper. A majority of the Committee shall constitute a quorum. The acts of a majority of the members present at any meeting at which a quorum is present and acts
approved in writing by a majority of the Committee in lieu of a meeting shall be deemed acts of the Committee. Each member of the Committee is entitled to, in good faith, rely upon any report or other information furnished to that member by any
officer or other associate of the Company, any subsidiary, the Company’s certified public accountants, or any executive compensation consultant or other professional retained by the Company to assist in the administration of the Plan.

 5. Awards. 
 The Committee shall
determine the type or types of Award(s) to be made to each Participant and shall set forth in the related Award Agreement the terms, conditions, performance requirements, limitations and restrictions applicable to each Award. Awards may include but
are not limited to those listed in this Section 5. Awards may be granted singly, in combination or in tandem. Awards may also be made in combination or in tandem with, in replacement or payment of, or as alternatives to, grants, rights or
compensation earned under any other plan of the Company, including the plan of any acquired entity. 
 (a) Stock Option—A stock
option is a grant of a right to purchase a specified number of shares of Stock at a stated price. The exercise price of Incentive Stock Options shall be not less than 100% of Fair Market Value on the date of grant and the exercise price of
Nonqualified Stock Options shall be not less than 85% of Fair Market Value on the date of grant. No individual may be granted options to purchase more than 277,777 shares during any Fiscal Year. 
 (b) Performance Share Award—A performance share award is an Award denominated in units of stock. Performance share awards will provide for
the payment of stock if performance goals are achieved over specified Performance Periods. 
 (c) Restricted Stock Award—A
restricted stock award is an Award of Stock which will vest if performance or other goals are achieved over specified Performance Periods. 
  

 3 

 (d) Performance Criteria under section 162(m) of the Code for Performance Share Awards, and Restricted
Stock Awards—The performance criteria for performance share awards and restricted stock awards made to any “covered employee” (as defined by section 162(m) of the Code) and which are intended to qualify as performance-based
compensation under section 162(m)(C) thereof, shall consist of objective tests based on one or more of the following: the Company’s earnings per share growth; earnings; earnings per share; cash flow; customer satisfaction; revenues; financial
return ratios; market performance; shareholder return and/or value; operating profits (including earnings before income taxes, depreciation and amortization); net profits; profit returns and margins; stock price; working capital; business trends;
production cost; project milestones; and plant and equipment performance. 
 (e) Nothing herein shall preclude the Committee from making any
payments or granting any Awards whether or not such payments or Awards qualify for tax deductibility under section 162(m) of the Code. No payments are to be made to a Participant if the applicable performance criteria are not achieved for a given
Performance Period. If the applicable performance criteria are achieved for a given Performance Period, the Committee has full discretion to reduce or eliminate the amount otherwise payable for that Performance Period. Under no circumstances may the
Committee use discretion to increase the amount payable to a Participant under a performance share award, or a restricted stock. 
 6. Payment of Awards.

 Payment of Awards may be made in the form of cash, stock or combinations thereof and may include such restrictions as the Committee
shall determine. Further, payments may be deferred, either in the form of installments or as a future lump-sum payment, in accordance with such procedures as may be established from time to time by the Committee. Dividends or dividend equivalent
rights may be extended to and made part of any Award denominated in stock or units of stock, subject to such terms, conditions and restrictions as the Committee may establish. The Committee may also establish rules and procedures for the crediting
of interest on deferred cash payments and dividend equivalents for deferred payments denominated in stock or units of stock. At the discretion of the Committee, a Participant may be offered an election to substitute an Award for another Award or
Awards of the same or different type. 
 7. Stock Option Exercise. 
 The price at which shares of Stock may be purchased under a stock option shall be paid in full in cash at the time of the exercise or, if permitted by the Committee, by means of tendering Stock or surrendering another
Award or any combination thereof. The Committee may determine other acceptable methods of tendering Stock or other Awards and may impose such conditions on the use of Stock or other Awards to exercise a stock option as it deems appropriate. In
addition, the optionee may effect a “cashless exercise” of a stock option in which the option shares are sold through a broker and a portion of the 

  

 4 

 
proceeds to cover the exercise price is paid to the Company, or otherwise in accordance with the rules and procedures adopted by the Committee. 

8. Tax Withholding. 
 Prior to the payment or
settlement of any Award, the Participant must pay, or make arrangements acceptable to the Company for the payment of, any and all federal, state and local tax withholding that in the opinion of the Company is required by law. The Company shall have
the right to deduct applicable taxes from any Award payment and withhold, at the time of delivery or vesting of shares of stock under the Plan, an appropriate number of shares for payment of taxes required by law or to take such other action as may
be necessary in the opinion of the Company to satisfy all obligations for withholding of such taxes. 
 9. Transferability. 
 No Award shall be transferable or assignable, or payable to or exercisable by, anyone other than the Participant to whom it was granted, except
(a) by law, will or the laws of descent and distribution, (b) as a result of the disability of a Participant or (c) that the Committee (in the form of an Award Agreement or otherwise) may permit transfers of Awards (other than
Incentive Stock Options) by gift or otherwise to a member of a Participant’s immediate family and/or trusts whose beneficiaries are members of the Participant’s immediate family, or to such other persons or entities as may be approved by
the Committee. 
 10. Amendment, Modification, Suspension or Discontinuance of the Plan. 
 The Board may amend, modify, suspend or terminate the Plan for the purpose of meeting or addressing any changes in law or other legal requirements or for
any other purpose permitted by law; provided, however, that no such amendment, modification, suspension or termination of the Plan shall adversely affect in any material way any Award previously granted under the Plan, without the written consent of
the Participant. Unless otherwise required by law, no such amendment shall require the approval of stockholders. 
 11. Termination of Employment. 

 If the employment of a Participant terminates, the status of the Award shall be as set forth in the Award Agreement. 
 12. Adjustments. 
 In the event of any change in the
outstanding Stock of the Company by reason of a stock split, stock dividend, combination or reclassification of shares, recapitalization, merger, or similar event, the Committee shall adjust appropriately: (a) the number of shares or kind of
Stock (i) available for issuance under the Plan, (ii) for which Awards may be granted to an individual Participant set forth in Section 5, and (iii) covered by outstanding 

  

 5 

 
Awards denominated in stock or units of stock; (b) the exercise and grant prices related to outstanding Awards; and (c) the appropriate Fair Market
Value and other price determinations for such Awards. In the event of any other change affecting the Stock or any distribution (other than normal cash dividends) to holders of Stock, such adjustments in the number and kind of shares and the
exercise, grant and conversion prices of the affected Awards as may be deemed equitable by the Committee, including adjustments to avoid fractional shares, shall be made to give proper effect to such event. In the event of a corporate merger,
consolidation, acquisition of property or stock, separation, reorganization or liquidation, the Committee shall be authorized to cause to issue or assume stock options, whether or not in a transaction to which section 424(a) of the Code applies, by
means of substitution of new stock options for previously issued stock options or an assumption of previously issued stock options. In such event, the aggregate number of shares of Stock available for issuance under Awards under Section 3,
including the individual Participant maximums set forth in Section 5, will be increased to reflect such substitution or assumption. 
 13.
Miscellaneous. 
 (a) Any notice to the Company required by any of the provisions of the Plan shall be addressed to the chief human
resources officer of the Company in writing, and shall become effective when it is received. 
 (b) The Plan shall be unfunded and the
Company shall not be required to establish any special account or fund or to otherwise segregate or encumber assets to ensure payment of any Award. 
 (c) Nothing contained in the Plan shall prevent the Company from adopting other or additional compensation arrangements or plans, subject to stockholder approval if such approval is required, and such arrangements or plans may be either
generally applicable or applicable only in specific cases. 
 (d) No Participant shall have any claim or right to be granted an Award under
the Plan and nothing contained in the Plan shall be deemed or be construed to give any Participant the right to be retained in the employ of the Company or to interfere with the right of the Company to discharge any Participant at any time without
regard to the effect such discharge may have upon the Participant under the Plan. Except to the extent otherwise provided in any plan or in an Award Agreement, no Award under the Plan shall be deemed compensation for purposes of computing benefits
or contributions under any other plan of the Company. 
 (e) The Plan and each Award Agreement shall be governed by the laws of the State of
Delaware, excluding any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of the Plan to the substantive law of another jurisdiction. Unless otherwise provided in the Award Agreement, recipients
of an Award under the Plan are deemed to submit to the exclusive jurisdiction and venue of the federal 

  

 6 

 
or state courts of Missouri, County of St. Louis, to resolve any and all issues that may arise out of or relate to the Plan or any related Award Agreement.

 (f) The Committee shall have full power and authority to interpret the Plan and to make any determinations thereunder, and the
Committee’s determinations shall be binding and conclusive. Determinations made by the Committee under the Plan need not be uniform and may be made selectively among individuals, whether or not such individuals are similarly situated.

 (g) If any provision of the Plan is or becomes or is deemed invalid, illegal or unenforceable in any jurisdiction, or would disqualify the
Plan or any Award under any law deemed applicable by the Committee, such provision shall be construed or deemed amended or limited in scope to conform to applicable laws or, in the discretion of the Committee, it shall be stricken and the remainder
of the Plan shall remain in full force and effect. 
 (h) The Plan was adopted by the Board on March 25, 2002 subject to approval of the
stockholders of the Company within 12 months of the date it was adopted. Awards may be granted prior to such approval, but no such Award may be exercised, vested or settled prior to such approval, and if such approval is not obtained, any such Award
shall be void ab initio and of no force or effect. If such approval is obtained, no further awards shall be granted under the Stereotaxis, Inc. 1994 Stock Option Plan 
 (i) Subject to earlier termination pursuant to Section 10, the Plan will terminate on March 25, 2012. Awards outstanding at the termination of the Plan will not be affected by such termination. 

 

 7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00127-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00127-of-00352.parquet"}]]